Ethylenglykol-dibut-3-ensaeureester | 14019-83-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Ethylenglykol-dibut-3-ensaeureester
• 英文别名: ethylene vinyl-acetate；(Carbamoylamino)peroxyurea；2-but-3-enoyloxyethyl but-3-enoate
• CAS: 14019-83-1
• 化学式: C₁₀H₁₄O₄
• 分子量: 198.219
• InChiKey: BZUFKMXELVWQIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Methods for synthesizing organoboronic compounds and products thereof
  申请人：Walter Armin

  公开号：US20050119226A1

  公开（公告）日：2005-06-02

  Organoboronic acids, for example Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH) 2 , are made by hydrolysing their diethanolamine adducts under conditions which avoid substantial C—B bond breakage. The product acids are substantially free of degradation product derived from cleavage of the C—B bond thereof. The acids are used to make base addition salts thereof. The salts are formulated into anti-thrombotic pharmaceutical formulations.

  有机硼酸，例如Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2，是通过在避免大量C—B键断裂的条件下水解它们的二乙醇胺加合物制备的。所得的产物酸基本上不含有从C—B键裂解产生的降解产物。这些酸用于制备它们的碱盐。这些盐被配制成抗血栓药物配方。
• [EN] INHIBITORS OF RETINALDEHYDE DEHYDROGENASES AND METHODS OF USE<br/>[FR] INHIBITEURS DE RÉTINALDÉHYDE DÉSHYDROGÉNASES ET MÉTHODES D'UTILISATION
  申请人：UNIV OKLAHOMA

  公开号：WO2017049110A1

  公开（公告）日：2017-03-23

  Compounds having inhibitory activity against retinaldehyde dehydrogenases (RALDHs). The compounds can be used, for example, to inhibit synthesis of retinoic acid for the treatment of refractive error disorders such as myopia, and as infertility treatments by inhibiting spermatogenesis.

  具有抑制视黄醛脱氢酶（RALDHs）活性的化合物。这些化合物可以用于抑制视黄酸的合成，治疗近视等屈光不正疾病，以及通过抑制精子生成来作为不孕症治疗。
• [EN] SULPHONAMIDE DERIVATIVES<br/>[FR] DERIVES SULFONAMIDES
  申请人：BIOTIE THERAPIES CORP

  公开号：WO2005090298A1

  公开（公告）日：2005-09-29

  The invention relates to sulphonamide derivatives of formula (I), where RC is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or RC forms together with the phenyl ring to which it is attached a benzodioxolyl group, or RC is -NR1R2, RA is a group having the formula (A), (B) or (C) RB is hydrogen or alkyl. The invention also relates to the use of derivatives of formula (I) as inhibitors for collagen receptor integrins and a process for preparing sulphonamides of formula (I).

  这项发明涉及式(I)的磺胺衍生物，其中RC是可选择取代的含有一个或多个N原子的4-6元杂环环，或者RC与其连接的苯环一起形成苯二氧杂环基团，或者RC是-NR1R2，RA是具有式(A)、(B)或(C)的基团，RB是氢或烷基。该发明还涉及将式(I)的衍生物用作胶原受体整合素的抑制剂以及制备式(I)的磺胺衍生物的方法。
• Sulphonamide Derivatives
  申请人：Smith David

  公开号：US20080255169A1

  公开（公告）日：2008-10-16

  The invention relates to sulphonamide derivatives of formula (I), where R C is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or R C forms together with the phenyl ring to which it is attached a benzodioxolyl group, or R C is —NR 1 R 2 , R A is a group having the formula R B is hydrogen or alkyl. The invention also relates to the use of derivatives of formula (I) as inhibitors for collagen receptor integrins and a process for preparing sulphonamides of formula (I).

  该发明涉及式(I)的磺胺基衍生物， 其中 R C 是可选取代的含有一个或多个N原子的4-6元杂环环，或 R C 与其连接的苯环一起形成苯二氧杂基团，或 R C 是-NR 1 R 2 ， R A 是具有式的基团 R B 是氢或烷基。 该发明还涉及将式(I)的衍生物用作胶原受体整合素的抑制剂以及制备式(I)的磺胺基的方法。
• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES 11,13-MODIFIÉES DESTINÉES AU TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2018183781A1

  公开（公告）日：2018-10-04

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

  提供的是化合物、包含该化合物的药物组合物、制备该化合物的方法，以及使用该化合物和组合物治疗与电压门控钠通道功能相关的病症的方法，其中所述化合物是根据公式(I)的11,13-修饰的石房蛤毒素：其中R4、R4a、R7、R7a和X2如本文所述。